Predictive technology to impact clinical trial design and outcomes

Available for research use only and protected by 3 patents, QyPredict® has the potential to improve targeted patient selection in clinical trials and prediction of disease progression in patients.

QyPredict® is the future, and the future is here.

Being developed for automated prediction of clinical disease progression based on a patient’s MRI and clinical data and the use of robust algorithms scanning our normative dataset of 10,000 brain scan images, QyPredict® aims to transform clinical trials and patient care.

The ability to predict the onset of a CNS disease is within our reach. That’s why Qynapse and our team of world-renowned neuroscience experts and principal investigators are dedicated to the continued development of QyPredict®.

For clinical trials, QyPredict® equips researchers with the ability to adjust patient selection and predict clinical progression, increasing the likelihood of trial success.

For physicians, we are exploring the potential to predict a patient’s individual disease trajectory, which would transform and improve timely intervention and treatment plans, potentially significantly improving quality of life and outcomes.

Doctor looking at brain scan

Transform your Clinical Trial.


Qyscore® is a medical device software FDA-cleared – class II. 

Indications for Use in the U.S. (FDA): QyScore® is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures and lesions from a set of MR images. Volumetric data may be compared to reference percentile data. QyScore is not intended for use in clinical scenarios that require evaluation of the number of the white matter hyperintensities.